000100 on Korean Stock Exchange

Yuhan

Logo: Yuhan Corporation, Public domain, via Wikimedia Commons3

South Korean pharmaceutical company

Yuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.2 It was founded by Ilhan New.1 Its shares trade on Korean Stock Exchange under the symbol 000100.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1926Founded1

Compare with another stock.

  • Ticker000100 on Korean Stock Exchange1
  • Industrypharmaceutical industry1
  • HeadquartersSeoul1
  • Websitewww.yuhan.co.kr
  • Legal formjusik hoesa1

Yuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.2

The story

Founded by Ilhan New in 1926.1

Leadership

Who has led Yuhan, and when. Pick a name to see everywhere that person has worked.

Products and brands

Yuhan Brands

Pharmaceutical

Non-Pharm/Medical Care

Health Food

Dental/Tooth Care

Read the full text

Chemical Cosmetic

Living Product

Animal Pharmaceuticals

Other Brands

Arm & Hammer

From Wikipedia’s article on Yuhan, shared under CC BY-SA 4.0.4

Timeline

  1. Nov 1, 1962Went public Listed on Korean Stock Exchange1
  2. 1926Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Jun 19, 2027Phase 2 trial readout expected Phase 2 trial of Lesigercept in Allergic Diseases: primary completion expected Jun 19, 2027 (ClinicalTrials.gov NCT07415551).5
  2. Jun 2027Phase 1/2 trial readout expected Phase 1/2 trial of YH32364 in EGFR Overexpression: primary completion expected Jun 2027 (ClinicalTrials.gov NCT06975410).6

Drug trials and FDA: recently

  1. Jan 15, 2026Phase 3 trial completed Phase 3 trial of YHP2401, YHR2402 and others in Acute Bronchitis: primary completion Jan 15, 2026, no results posted yet (ClinicalTrials.gov NCT07111468).7

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar